Breast Cancer, Diabetes, Pancreatic Cancer, Pre Diabetes
Conditions
Keywords
Glucose Monitoring, 19-315
Brief summary
The purpose of this study is to see if continuous glucose monitoring can identify how often people who have pre-diabetes or medical obesity or well-controlled diabetes experience very high glucose values while receiving chemotherapy for breast cancer or pancreatic.
Interventions
None listed
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 18 or older undergoing neoadjuvant chemotherapy regimens including taxane and/or anthracycline for breast cancer. * Patient aged 18 or older undergoing any chemotherapy regimen for pancreatic cancer * Have 'high metabolic risk(either pre-diabetes, obesity, or well-controlled diabetes) defined as either: * Pre-diabetes and/or obesity group: one or more of known HbA1c 5.7-6.5%, fasting glucose \> 100 mg/dL, or BMI \> 30 * Well-controlled diabetes: Known HbA1c \< 7.5 on lifestyle alone or up to one oral antidiabetic agent * Any patient undergoing treatment for pancreatic adenocarcinoma on either no antidiabetic agent or up to one oral antidiabetic agent
Exclusion criteria
* Patients with type 1 diabetes, a history of hospitalization for either hyperglycemia or ketoacidosis, a history of hypoglycemia requiring hospitalization, rashes or other skin reactions that would preclude placement of the CGM * Use of anticoagulants or antiplatelet agents other than aspirin * Platelet count \< 50 K/μL within 60 days prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| severe hyperglycemia | 1 year | glucose \> 400 mg/dL for over 3 contiguous hours |
Countries
United States
Outcome results
None listed